Penumbra Inc Stock
Penumbra Inc Stock
A loss of -1.720% shows a downward development for Penumbra Inc.
Pros and Cons of Penumbra Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Penumbra Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Penumbra Inc | -1.720% | 1.067% | 5.754% | 8.121% | 8.407% | 19.563% | 46.607% |
| Icu Medical Inc. | 0.830% | -1.613% | 2.521% | -19.737% | -17.007% | -17.007% | -23.750% |
| Bio-Rad Labs Inc. A | 1.740% | -1.966% | 1.317% | -16.522% | -14.263% | -31.823% | -41.201% |
| Neogen Corp. | 6.310% | 16.505% | 8.108% | -52.000% | -50.000% | - | - |
News
Penumbra (PEN) Q2 Revenue Jumps 13%
Penumbra (NYSE:PEN), a medical device innovator focused on clot removal and vascular care, reported its second quarter 2025 results on July 29, 2025. The company delivered $339.5 million in GAAP
